Reliable Brokers
Online Investing
Alerts & Analysis
Easy Trading

UT Galveston develops chikungunya vaccine

Update : 13 Jul 2017, 07:52 PM
Researchers from the medical branch of the University of Texas in Galveston (UT Galveston) developed a prototype vaccine for chikungunya fever last year, using an insect-specific hybrid of the virus that does not affect humans, reported Science Daily on December 19, 2016. Though the vaccine had yet to be tested on human subjects, animal trials proved spectacularly effective on both rodents and non-human primates. Test subjects that had the vaccine administered developed a strong immunity to chikungunya, producing neutralizing antibodies that lasted over 290 days within four days of administration. The findings were detailed in Nature Medicine. According to Science Daily, vaccine development usually involves a trade-off between the time for a vaccine to become effective and the chances for it to compromise the subject's health and safety. Live-attenuated vaccines, made from weakened versions of the original virus, prove effective more quickly but pose a greater risk of infecting those administered with it. On the other hand, inactivated vaccines pose less of a threat to the health of subjects, but usually require boosters and multiple doses to prove effective. In order to overcome the aforementioned obstacles and produce a vaccine that is both rapidly effective and safe, the researchers at UT Galveston developed the prototype vaccine using the Eilat virus as a platform. This virus only infects insects and is harmless to humans. Once an Eilat virus clone was merged with structural proteins from chikungunya, the resulting hybrid was found to structurally identical to naturally occurring varieties of the chikungunya virus. However, the hybrid only replicates well in mosquitoes and not in mammals.
Top Brokers